Changing the course of autoimmune disease

Inspired by patients. Driven to make an impact.

Aurinia’s Response to COVID-19

View

Latest News

May 14, 2021 • 6:05am EDT

Aurinia Pharmaceuticals to Participate in Two Upcoming Investor Conferences

Read Press Release View All News

May 10, 2021 • 4:05pm EDT

Aurinia Unveils Patient Navigation Grant Program to Address Access Barriers for Individuals Living with Lupus and Lupus Nephritis

Read Press Release View All News

May 10, 2021 • 6:05am EDT

Aurinia Announces Publication of AURORA 1 Phase 3 Study Results with LUPKYNIS™ (voclosporin) in The Lancet

Read Press Release View All News